Skip to main content
In stock | Immunotherapy (Monoclonal Antibody)

Alemtuzumab

Oncology Type Hematologic (CLL)
Drug Class / Mechanism Anti-CD52 mAb
No Image
Description

Alemtuzumab is classified as an Anti-CD52 mAb, sourced for use within our Immunotherapy (Monoclonal Antibody) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Immunotherapy (Monoclonal Antibody)
Oncology Type Hematologic (CLL)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3